News and Press

ACELYRIN, INC., Affibody AB, and Inmagene Bio Announce Positive Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis
May 03, 2022

Affibody AB, and Inmagene Biopharmaceuticals Co., Ltd., today announced that a 16-week, global, Phase 2 clinical trial of izokibep in 135 patients with psoriatic arthritis (PsA) met its primary endpoint of ACR50.

Bruce Cozadd joins ACELYRIN, INC. Board of Directors
March 17, 2022

Innovative clinical-stage biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies, today announced the appointment of Bruce C. Cozadd, co-founder and CEO of Jazz Pharmaceuticals, to its board of directors.

ACELYRIN, INC. Affibody AB, and Inmagene Biopharmaceuticals Announce Positive Interim Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis
December 14, 2021

Affibody AB, and Inmagene Biopharmaceuticals, today announced that a 16-week, global, Phase 2 clinical trial of izokibep in patients with psoriatic arthritis (PsA) met its primary endpoint in a pre-specified interim analysis.

ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep, a Late-Stage IL-17A Inhibitor to Treat Inflammatory Diseases
November 16, 2021

Series B led by AyurMaya, an affiliated fund of Matrix Capital Management, Surveyor Capital (a Citadel company), and Westlake Village BioPartners